Items where authors include "Cook, M"

Article

Royle, K-L orcid.org/0000-0003-0225-1199, Coulson, AB, Ramasamy, K et al. (26 more authors) (2022) Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. BMJ Open, 12 (11). e063037. ISSN 2044-6055

Auner, HW, Brown, SR orcid.org/0000-0002-7975-7537, Walker, K et al. (9 more authors) (2022) Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results. Blood Cancer Journal, 12 (4). 52. ISSN 2044-5385

Rana, R, Cockwell, P, Drayson, M et al. (8 more authors) (2020) Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. Blood Advances, 4 (22). pp. 5836-5845. ISSN 2473-9529

Hinsley, S, Walker, K, Sherratt, D et al. (13 more authors) (2020) The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. Trials, 21 (1). 826. 826-.

Yadav, P, Cockwell, P, Cook, M et al. (10 more authors) (2018) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma. BMC Nephrology, 19 (1). 178. ISSN 1471-2369

Chapman, MA, Sive, J, Ambrose, J et al. (27 more authors) (2018) RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. Blood, 132 (20). pp. 2154-2165. ISSN 0006-4971

Striha, A orcid.org/0000-0003-3363-8417, Ashcroft, AJ, Hockaday, A et al. (12 more authors) (2018) The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials, 19. 169. p. 169. ISSN 1745-6215

Fuentes, R orcid.org/0000-0001-8617-7381, Chapman, T, Cook, M et al. (3 more authors) (2017) Briefing: UK-RAS white paper in robotics and autonomous systems for resilient infrastructure. Proceedings of the Institution of Civil Engineers - Smart Infrastructure and Construction, 170 (3). pp. 72-79. ISSN 2397-8759

Cook, G, Iacobelli, S, van Biezen, A et al. (19 more authors) (2017) High dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: A retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. Haematologica, 102. pp. 160-167. ISSN 0390-6078

Gusev, A, Shi, H, Kichaev, G et al. (205 more authors) (2016) Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. NATURE COMMUNICATIONS, 7. ARTN 10979. ISSN 2041-1723

Chapman, RJ, Cook, M, Grimshaw, M et al. (1 more author) (2016) Placer-lode gold relationships in the Nansen placer district, Yukon. Yukon Exploration and Geology. pp. 63-78. ISSN 1718-8334

Schey, S, Brown, SR, Tillotson, A-L et al. (13 more authors) (2015) Bendamustine, thalidomide and dexamethasone combinationtherapy for relapsed/refractory myeloma patients: results ofthe MUKone randomized dose selection trial. British Journal of Haematology, 170 (3). pp. 336-348. ISSN 0007-1048

Mitra, A, Conway, C, Walker, C et al. (17 more authors) (2010) Melanoma sentinel node biopsy and prediction models for relapse and overall survival. British Journal of Cancer, 103 (8). pp. 1229-1236. ISSN 0007-0920

Proceedings Paper

Cook, G orcid.org/0000-0003-0223-3652, Parrish, C, Yong, K et al. (12 more authors) (2018) Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial. In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .

Hayes, AJ, Maynard, L, A'Hern, R et al. (7 more authors) (2015) Long term follow up of survival in a randomised trial of wide or narrow excision margins in high risk primary melanoma. In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology, 29 May - 02 Jun 2015, Chicago, IL, USA. American Society of Clinical Oncology .